CryoPort (NASDAQ:CYRX) Director Robert Hariri Sells 5,000 Shares

CryoPort, Inc. (NASDAQ:CYRX) Director Robert Hariri sold 5,000 shares of CryoPort stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $8.60, for a total value of $43,000.00. Following the sale, the director directly owned 26,275 shares in the company, valued at $225,965. The trade was a 15.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

CryoPort Stock Performance

Shares of CYRX stock opened at $8.86 on Friday. The business’s 50-day moving average price is $7.84 and its 200-day moving average price is $6.71. CryoPort, Inc. has a 12 month low of $4.58 and a 12 month high of $9.48. The firm has a market capitalization of $443.59 million, a price-to-earnings ratio of 6.66 and a beta of 1.88. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Equities research analysts forecast that CryoPort, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CYRX shares. BTIG Research lowered their price objective on CryoPort from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, July 7th. KeyCorp upgraded CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price objective for the company in a research report on Wednesday, August 6th. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Wednesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of CryoPort in a report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $12.00.

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently modified their holdings of the company. Cadian Capital Management LP boosted its position in shares of CryoPort by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock valued at $38,332,000 after buying an additional 609,021 shares during the last quarter. Millennium Management LLC boosted its position in shares of CryoPort by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after buying an additional 409,353 shares during the last quarter. Thematics Asset Management boosted its position in shares of CryoPort by 12.8% during the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after buying an additional 216,937 shares during the last quarter. Deutsche Bank AG boosted its position in shares of CryoPort by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock valued at $10,870,000 after buying an additional 12,864 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of CryoPort by 7.8% during the second quarter. Geode Capital Management LLC now owns 1,203,061 shares of the company’s stock valued at $8,977,000 after buying an additional 87,418 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.